Generic drugs: offering exceedingly good growth?

Generic drugs: offering exceedingly good growth?

In the world of asthma medication, there's a war approaching and GlaxoSmithKline (GSK) has just dodged the first bullet. The US Food and Drug Administration (FDA) has rejected Mylan's (US: MYL) first attempt at an unbranded version of GSK's top-selling respiratory drug Advair, thus delaying the inevitable sales decline of the original product.

To continue reading, register today

to enjoy limited access to the following:

  • Daily trading news
  • Funds coverage
  • Features on big investment themes
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now